This story was originally published on Oct. 29.

By Justin Petrone

In spite of reporting an uptick in revenues and posting a profit in the third quarter, Illumina last week said it was “disappointed“ by its performance because it fell short of analysts' estimates and its own guidance for the quarter.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.